#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

B-cell chronic lymphocytic leukemia. Part IV: Monoclonal antibody treatment options with alemtuzumab and rituximab


Authors: kT. Papají;  R. Urbanová;  V. Procházka;  K. Indrák
Authors‘ workplace: Hemato-onkologická klinika LF UPaFN Olomouc
Published in: Transfuze Hematol. dnes,13, 2007, No. 2, p. 48-55.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

B-cell chronic lymphocytic leukemia (B-CLL) is conventionally incurable lymphoproliferative disease. Modern chemotherapy can effectively affect disease course and survival in only small proportion of patients. Monoclonal antibodies represent new category of anticancerdrugs that mediate cell death utilizing several mechanism different from classical chemotherapy including direct pro-apoptotic effect, complement – mediated cytotoxicity and antibody-dependent cellularcytotoxicity. Alemtuzumab (anti-CD52) and rituximab (anti-CD20) are currently widely used monoclonal antibodies in B-CLL. Alemtuzumab is approved forthe treatment of relapsing and resistant patients and recent pilot reports demonstrate its activity in eliminating the minimal residual disease. Rituximab have synergistic

anti-leukemic effect with fludarabine and cyclophosphamide and this combination will probably become gold standard in the first-line treatment of B-CLL.

Key words:
B-cell chronic lymphocytic leukemia, monoclonal antibodies, rituximab, alemtuzumab, residual disease


Sources

1. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated

stage B and C chronic lymphocytic leukemia patients. French Cooperative Group on Chronic Lymphocytic Leukemia. Blood

2001; 98: 2319–2325.

2. Robak T. Therapy of chronic lymphocytic leukemia with purine nucleoside analogues. Drugs Aging 2005; 22: 983–1012.

3. Keating MJ, O’Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine

regimens as initial therapy. Blood 1998; 92: 1165–1171.

4. Flinn IW, Jemiai Y, Bennett JM, et al. Fludarabine and cyclophosphamide achieves high complete response rate in patients with

previously untreated chronic lymphocytic leukemia. Blood 2001; 98: 633a.

5. Eichhorst B, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of

younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885–891.

6. Gilleece MH, Dexter TM. Effect of campath – 1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82: 807–812.

7. Hale G. CD52 (Campath1). J Biol Regul Homeost Agents 2001; 15: 386 – 391.

8. Dyer MJS, Hale G, Marcus RE, Waldmann H. Effects of Campath- 1 antibodies in vivo in patients with lymphoid malignancies:

influence of antibody isotype. Blood 1989; 73: 1431–1439.

9. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323–327.

10. Hale G, Dyer MJS, Clark MR, et al. Remission induction in non-Hodgkin’s lymphoma with reshaped human monoclonal antibody

Campath-1H. Lancet 1988; 2: 1394–1399.

11. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol 2000; 12: 574–581.

12. Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the Campath- 1 antigen (CD52) mediates growth inhibition in human Band

T-lymphoma cell lines, and subsequently emergence of CD52 – deficient cells. Immunology 1998; 95: 427–436.

13. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with

in vivo therapeutic responses to Campath-1H. Leuk Res 1998; 22: 185–191.

14. Österborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of Campath-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567–1574.

15. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891–3897.

16. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561.

17. Stilgenbauer S, Döhner H. Campath-1H induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347: 452–453.

18. Lozanski G, Nyla A, Flin IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p 53 mutations and deletions. Blood 2004; 103: 3278–3281.

19. Dyer MJS, Kelsey SM, Mackay HJ, et al. In vivo purging of residual disease in CLL with Campath-1H. Br J Haematol 1997; 97: 669–672.

20. Rai KR, Byrd JC, Peterson BL, Larson LA. A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) study 19901. Blood 2002; 100: 205a.

21. Moreton P, Kennedy B, Lucas M, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971–2979.

22. Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 2337–2342.

23. Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for untreating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002; 87: 695–700.

24. Bowen AL, Zomas A, Emmett E, et al. Subcutaneous Campath- 1H in fludarabine-resistant/relapsed chronic lymphocytic and Bprolymphocytic leukaemia. Br J Haematol 1997; 96: 617–619.

25. Stilgenbauer S, Winkler D, Krober A, et al. Subcutaneous Campath- 1H (alemtuzumab) in fludarabine-refractory CLL; interim analysis of the CLL2H study of the German CLL Study Group (GCLLSG). Blood 2004; 104: 478a.

26. Lundin J, Kimby E, Björkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath- 1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768–773.

27. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002; 99: 2245–2247.

28. Elter T, Bochmann P, Schulz H, et al. FluCam – a new, 4-weekly combination of fludarabine and alemtuzumab for patients with relapsed chronic lymphocytic leukemia. Blood 2004; 104: 2517a.

29. Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2005; 132: 3–12.

30. Keating M, Coutré S, Rai K, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004; 4: 220–227.

31. Stashenko P, Nadler LM, Hardy R, et al. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 1678–1685.

32. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signaling through lipid rafts. Immunology 2002; 107: 176–182.

33. Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and ymphomas: a model of human B cell differentiation. Blood 1984; 63:

1424–1433.

34. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383–3389.

35. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69: 584–591.

36. Grillo – López AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin. Oncol. 1999; 5 (Suppl. 14): 66–73.

37. Alas S, Emmanouilides S, Bonavida B, et al. Inhibition of interleukin- 10 by rituximab results in down – regulation of bcl-2 and senzitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin. Cancer Res. 2001; 7: 709–723.

38. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800–809.

39. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.

40. Lin TS, Byrd JC. Monoclonal antibody therapy in lymphoid leukemias. Adv Pharmacol 2004; 51: 127–167.

41. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21: 1746–1751.

42. O’Brien SM, Kantarjian H, Thomas DA, et al. Rituximab doseescalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165–2170.

43. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153–2164.

44. Schultz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002; 100: 3115–3120.

45. Savage DG, Cohen NS, Hesdorffer CS, et al. Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44: 477–481.

46. Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070–4078

47. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101: 6– 14.

48. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105: 49–53.

49. Byrd JC, Gribben JG, Peterson BL, et al. Select high risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia (CLL): Preliminary justification for risk-adapted therapy. Blood 2004; 104: 476a.

50. Del Principe MI, Del Poeta G, Maurillo L, et al. Addition of rituximab to fludarabine improves progression free survival in untreated ZAP-70 negative chronic lymphocytic leukemia. Blood 2004; 104: 477a.

51. Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol; 2005: 4079–4088.

52. Casula P, Sorano G, Pulixi D, et al. Oral fludarabine and cyclophosphamide plus rituximab in the treatment of the chronic lymphocytic leukemia. Blood 2005; 106: 5039a.

53. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymhocytic leukemia and high lymphocyte counts after treatment with anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217–2224.

54. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999; 17: 791–795.

55. Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002; 16: 2092–2095.

56. Zaja F, Vianelli N, Sperotto A, et al. Anti-CD20 therapy for chronic lymphocytic leukemia - associated autoimmune diseases. Leuk Lymphoma 2003; 44: 1951–1955.

57. Ghazal H. Succesful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood 2002; 99: 1092–1094.

58. Faderl S, Thomas AD, O’Brien SM, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101: 3413–3415.

Labels
Haematology Internal medicine Clinical oncology

Article was published in

Transfusion and Haematology Today

Issue 2

2007 Issue 2

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#